US35104E1001

4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones

February 28, 2025 16:05 ET  | Source: 4D Molecular Therapeutics, Inc. Presented positive interim data through 52 weeks and beyond…

2 weeks ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

February 08, 2025 14:30 ET  | Source: 4D Molecular Therapeutics, Inc. 3E10 vg/eye achieved an 83% reduction in injection burden…

1 month ago

4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population

January 29, 2025 08:00 ET  | Source: 4D Molecular Therapeutics, Inc. Initial interim 52-week results from Phase 2b Population Extension…

2 months ago